Literature DB >> 12814336

Dermabrasion in dermatology.

Michael H Gold1.   

Abstract

Dermabrasion has been used for a number of years to treat a variety of dermatologic conditions, including facial skin resurfacing and scar revision. The popularity of this procedure has diminished with the advent of newer procedures including chemical exfoliation, laser resurfacing, non-ablative laser resurfacing, and microdermabrasion. Dermabrasion found its niche in treating acne and traumatic facial scars, and in cosmetic facial resurfacing. Small, portable hand-held dermabraders are the most popular units available today and are able to generate rotation speeds of 18,000-35,000 revolutions per minute. End pieces, including wire brushes, diamond fraises and serrated wheels, attach to the end of the dermabrader to allow precise resurfacing and treatment. As with all cosmetic surgical procedures, appropriate patient selection and room preparation (with appropriate lighting and monitoring equipment) are essential to assure optimal outcomes with the dermabrasion procedure. Patients must understand all of the potential risks, benefits and limitations associated with the procedure. Patients must also be aware of alternative therapies that are available. Dermabrasion is technique-dependent and the surgeon should be well versed on the technique prior to performing this therapy. Gentian violet solution is used to delineate the areas to be treated. Refrigerant topical anesthesia is used to freeze the skin prior to the procedure. Holding the skin taut, the dermabrasion procedure occurs in a routine manner, treating one anatomic unit at a time. Postoperatively, patients may have an open or closed dressing system. Postoperative medical treatment is also recommended, including the use of antiviral agents, antibacterials and corticosteroids. The re-epithelialization process is usually complete in 5-7 days and residual erythema is common for up to 4 weeks. Adequate sun protection is essential following dermabrasion. Dermabrasion has also been used in combination with other dermatologic procedures, including chemical exfoliation, soft tissue augmentation and laser procedures, to enhance the results of dermabrasion. Dermabrasion remains a useful facial skin resurfacing and scar revision technique, particularly when performed by a trained and skilled surgeon. Most dermatologic surgeons argue that pure dermabrasion is a useful modality in skilled surgical hands and should be considered when appropriate.

Entities:  

Mesh:

Year:  2003        PMID: 12814336     DOI: 10.2165/00128071-200304070-00003

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  5 in total

Review 1.  Generalized Anetoderma after Intravenous Penicillin Therapy for Secondary Syphilis in an HIV Patient.

Authors:  Jason Emer; Daniel Roberts; Harleen Sidhu; Robert Phelps; Herbert Goodheart
Journal:  J Clin Aesthet Dermatol       Date:  2013-08

2.  Oral isotretinoin in photoaging: objective histological evidence of efficacy and durability.

Authors:  Bruna Souza Felix Bravo; David Rubem Azulay; Ronir Raggio Luiz; Carlos Alberto Mandarim-De-Lacerda; Tullia Cuzzi; Mônica Manela Azulay
Journal:  An Bras Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.896

3.  Modified Procedure of Noncultured Epidermal Suspension Transplantation: Changes are the Core of Vitiligo Surgery.

Authors:  Anantha Prasad Holla; Ravinder Kumar; Davinder Parsad; Aj Kanwar
Journal:  J Cutan Aesthet Surg       Date:  2011-01

4.  Effects of the combined PDL/Nd:YAG laser on surgical scars: vascularity and collagen changes evaluated by in vivo confocal microscopy.

Authors:  Krisztina Vas; Magdolna Gaál; Erika Varga; Réka Kovács; Balázs Bende; Adám Kocsis; Lajos Kemény
Journal:  Biomed Res Int       Date:  2014-09-09       Impact factor: 3.411

Review 5.  Wounding Therapies for Prevention of Photocarcinogenesis.

Authors:  Timothy C Frommeyer; Craig A Rohan; Dan F Spandau; Michael G Kemp; Molly A Wanner; Elizabeth Tanzi; Jeffrey B Travers
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.